Open AccessCOVID‐19 induced bradyarrhythmia and relative bradycardia: An overview
Author(s) -
Douedi Steven,
Mararenko Anton,
Alshami Abbas,
AlAzzawi Mohammed,
Ajam Firas,
Patel Swapnil,
Douedi Hani,
Calderon Dawn
Publication year - 2021
Publication title -
journal of arrhythmia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 21
eISSN - 1883-2148
pISSN - 1880-4276
DOI - 10.1002/joa3.12578
Subject(s) - bradycardia , medicine , myocarditis , epidemiology , pathogenesis , covid-19 , disease , cardiology , incidence (geometry) , intensive care medicine , heart rate , blood pressure , infectious disease (medical specialty) , physics , optics
Novel coronavirus 2019 (COVID‐19) has been the focus of the medical community since its emergence in December 2019 and has already infected more than 100 million patients globally. Primarily described to cause a respiratory illness, COVID‐19 has been found to affect almost every organ system. Bradycardia is a newly recognized ramification of COVID‐19 that still has unknown prognostic value. Studies have shown an increase in the incidence of arrhythmias, cardiomyopathies, myocarditis, acute coronary syndromes, and coagulopathies in infected patients as well as an increased risk of mortality in patients with preexisting cardiovascular disease. While the pathogenesis of bradycardia in COVID‐19 may be multifactorial, clinicians should be aware of the mechanism by which COVID‐19 affects the cardiovascular system and the medication side effects which are used in the treatment algorithm of this deadly virus. There has yet to be a comprehensive review analyzing bradyarrhythmia and relative bradycardia in COVID‐19 infected patients. We aim to provide a literature review including the epidemiology, pathogenesis, and management of COVID‐19 induced bradyarrhythmia.